RNA-seq of U87MG and patient sample 2 (PS2) at different time points post-radiation treatment

Glioblastoma (GBM) is a malignant grade IV brain tumor, and despite the multimodal therapeutic approaches, which include surgery and chemo-radiotherapy, recurrence is inevitable, arising from therapy-resistant residual cells. To study the residual population's survival mechanism(s), we established a radiation survival model from GBM cells and primary patient cultures (parent or P). Interestingly, the residual cells (RS), although non-proliferative and enriched in multinucleated and giant cell phenotype (MNGCs) phenotype, underwent unconventional cell division (end of residual or ERS phase) in the absence of spindle structures and cytokinesis to generate aggressive relapse (R). RNA sequencing of GBM cell line U87MG and patient sample 2 (PS2) at different time points post-radiation treatment was performed to understand the molecular players behind this residual cell division.